

## VETOQUINOL AND ORION PHARMA ANIMAL HEALTH ENTER INTO DISTRIBUTION COLLABORATION

**Vétoquinol and Orion Pharma Animal Health - a part of Orion Corporation - announce their collaboration regarding the distribution of Dexdomitor®, Antisedan®, Domitor® and Domosedan®. Vétoquinol becomes distributor in selected European countries of these Orion Sedative products.**

The collaboration between the companies is effective as of 1 January 2015 and Vétoquinol is responsible for marketing the Orion sedatives range to customers in United Kingdom, Germany, France, Ireland, The Netherlands, Belgium, Luxembourg and Italy.

**Niclas Lindstedt**, Vice President of Orion Pharma Animal Health commented:

*“Orion Pharma Animal Health foresees that this new alliance with a dedicated and recognized partner will further strengthen the position with customers of the well accepted Orion sedatives range. Vétoquinol has a particularly strong focus on the companion animal pain and sedation segments in the concerned countries.”*

**Matthieu Frechin**, CEO of Vétoquinol commented:

*“The inclusion of the sedative products from Orion Pharma Animal Health in our pain and surgery product range will further reinforce our offer to our customers; it is a an additional proof of our willingness to be a partner of choice for all vet surgeons in the field of pain and anesthesia.”*

### **About Dexdomitor®, Antisedan®, Domitor® and Domosedan®**

The Orion sedatives range include Dexdomitor® 0.5 mg / ml, Dexdomitor® 0.1 mg/ml, Domitor®, Antisedan®, Domosedan® and Domosedan Gel®. The products belong to the alpha 2 –agonists and antagonist segment. Recent additions to the Orion Pharma Animal Health Sedatives segment are Domosedan Gel® for sublingual dosing for horses and Dexdomitor® 0.1 mg / ml for accurate and precise dosing for small sized dogs and cats.



#### **About Vétoquinol**

Vétoquinol is a leading global player in the animal health sector serving both the livestock (cattle and pigs) and pet (dogs and cats) markets.

A family owned, pure player, Vétoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vétoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. Vétoquinol employs 1,988 people world-wide.

Vétoquinol has been listed on NYSE Euronext Paris since 2006 (symbol: VETO).

**For more information:** [www.vetoquinol.com](http://www.vetoquinol.com).

#### **About Orion**

Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion develops inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2014 amounted to EUR 1,015 million and the Company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.

**For more information:** [www.orion.fi](http://www.orion.fi)

### **OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.**

For more information, contact:

#### **VETOQUINOL**

Investor Relations

Régis Vimal du Monteil

Tel.: +33 (0)3 84 62 59 88

[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

#### **KEIMA COMMUNICATION**

Investor Relations and Media Relations

Emmanuel DOVERGNE

Tel.: +33 (0)1 56 43 44 63

[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)

#### **ORION PHARMA ANIMAL HEALTH**

Mr. Niclas Lindstedt, Vice President

Email: [niclas.lindstedt@orionpharma.com](mailto:niclas.lindstedt@orionpharma.com)

Tel. +358 50 966 4116